publication date: Dec. 18, 2010
In this issue:
NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.
Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.
Appreciation: Quack-Buster Saul Green Used Science to Debunk Alternative Medicine Claims.
Download (PDF 393KB)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.